OTCMKTS:CMOPF Cosmo Pharmaceuticals (CMOPF) Stock Price, News & Analysis C$66.08 -2.12 (-3.11%) As of 11/2/2026 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Cosmo Pharmaceuticals Stock (OTCMKTS:CMOPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cosmo Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$66.08▼C$66.0850-Day RangeC$59.02▼C$74.3052-Week RangeC$59.02▼C$169.90Volume1 shsAverage Volume394 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cosmo Pharmaceuticals N.V. is an international pharmaceutical company focused on developing, manufacturing and commercializing treatments for gastrointestinal and dermatological conditions. The company uses its proprietary MMX drug-delivery technology to formulate therapies designed to release active ingredients at targeted locations in the gastrointestinal tract. Cosmo’s gastrointestinal portfolio includes products for inflammatory bowel disease and other digestive disorders, including mesalamine-based therapies and rifamycin-based treatments. Through its subsidiary Cassiopea, the company also develops and commercializes dermatology products, including Winlevi (clascoterone), a topical treatment for acne. Founded in 1997, Cosmo serves healthcare markets internationally through licensing, partnerships and direct commercial activities. The company has operational roots in Italy and is headquartered in Ireland. Its leadership includes Chief Executive Officer Alessandro Della Chà.AI Generated. May Contain Errors. Read More Receive CMOPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cosmo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMOPF Stock News HeadlinesCosmo N.V. (CMOPF) Discusses Positive Phase 2 Results and Differentiation of Rifamycin 1% Gel in Ulcerative Colitis and Proctitis TranscriptOctober 21, 2026 | seekingalpha.comCosmo’s Rifamycin Gel Hits Key Phase 2 Mark in Distal Ulcerative ColitisOctober 19, 2026 | tipranks.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare. | Digest Publishing (Ad)Cosmo Pharmaceuticals to Change SIX Ticker to CMHC, Aligning Brand With Health-Focused StrategyAugust 14, 2026 | tipranks.comInvitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026July 25, 2026 | theglobeandmail.comCosmo N.V. (CMOPF) Q2 2026 Earnings Call TranscriptJuly 23, 2026 | seekingalpha.comCosmo NV (CMOPF) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...July 23, 2026 | finance.yahoo.comCosmo sets date for 2026 half-year results and investor webcastJuly 1, 2026 | tipranks.comSee More Headlines CMOPF Stock Analysis - Frequently Asked Questions How have CMOPF shares performed this year? Cosmo Pharmaceuticals' stock was trading at C$133.00 at the beginning of 2026. Since then, CMOPF shares have decreased by 50.3% and is now trading at C$66.08. How do I buy shares of Cosmo Pharmaceuticals? Shares of CMOPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CMOPF Previous SymbolOTC:CMOPF CIKN/A Webwww.cosmopharma.com Phone353 1 817 0370FaxN/AEmployees324Year Founded1997Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (OTCMKTS:CMOPF) was last updated on 11/2/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...Investors Alley | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cosmo Pharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Share Cosmo Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
